J. Goldman & CO LP Biohaven Pharmaceutical Holding CO Ltd. Transaction History

J. Goldman & CO LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$99.73 - $148.48 $2 Million - $2.98 Million	-20,096 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$98.85 - $138.91 $1.99 Million - $2.79 Million	20,096 New	20,096 $2.79 Million
Q3 2019 Nov 14, 2019	SELL	$37.38 - $49.47 $373,800 - $494,700	-10,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$39.79 - $67.01 $37,044 - $62,386	931 Added 10.27%	10,000 $438,000
Q1 2019 May 14, 2019	BUY	$34.52 - $53.29 $105,596 - $163,014	3,059 Added 50.9%	9,069 $467,000
Q4 2018 Feb 14, 2019	SELL	$29.75 - $42.9 $609,220 - $878,506	-20,478 Reduced 77.31%	6,010 $222,000
Q3 2018 Nov 14, 2018	BUY	$32.79 - $43.0 $528,574 - $693,160	16,120 Added 155.48%	26,488 $995,000
Q2 2018 Aug 14, 2018	SELL	$23.62 - $42.29 $2.4 Million - $4.3 Million	-101,623 Reduced 90.74%	10,368 $410,000
Q1 2018 May 15, 2018	BUY	$22.49 - $34.56 $2.36 Million - $3.62 Million	104,794 Added 1456.08%	111,991 $2.89 Million
Q4 2017 Feb 16, 2018	BUY	$20.44 - $35.56 $147,106 - $255,925	7,197	7,197 $194,000

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.